

March 23<sup>rd</sup>, 2021

**Subject: Introduction of Fibryga® Kit: Now Co-Packaged with Water for Injection**

Dear Health Care Professional,

Octapharma Canada is pleased to announce that Fibryga® (Fibrinogen Concentrate, Octapharma) kit will now include co-packaged sterile Water For Injection (WFI).

The new Fibryga Kit will include:

- 1gram of Lyophilised Fibrinogen concentrate as powder
- 50 ml sterile Water For Injection (WFI)
- 1 transfer device (Octajet) to reconstitute
- A particle filter
- Package leaflet



With everything you need to reconstitute Fibryga in one comprehensive kit, stocking Fibryga will simplify managing inventory and greatly improve your reconstitution experience.

**Indication:**

Fibryga® is indicated for the treatment of acute bleeding episodes and perioperative prophylaxis in adult and pediatric patients with congenital afibrinogenemia and hypofibrinogenemia.

Fibryga® is also indicated for the management of bleeds in Acquired Fibrinogen Deficiency (AFD)

**New Infusion rate:** Important changes have been made to the dosing and infusion rate of Fibryga<sup>1</sup>. The standard dose of 4 g in AFD can be infused in 10 minutes (maximum rate of 20 mL per minute)<sup>1</sup>. The ability to rapidly infuse Fibryga® 75% faster can be meaningful in urgent surgical situations. Further, Fibryga® can be reconstituted within approximately 5 minutes using the included Octajet® transfer device.

**Room temperature storage and handling:** Fibryga® can be stored at +2°C to +25°C for up to 36 months from the date of manufacture. After reconstitution Fibryga® is stable for up to 24 hours at +25°C.

Fibryga® co-packaged kit is available for ordering using the standard CBS product order form. Orders can be placed starting in April.

---

Octapharma Canada Inc.  
214 King Street West  
Suite 308  
Toronto, ON M5H 3S6

Phone: (416) 531-5533  
Email: [info@octapharma.ca](mailto:info@octapharma.ca)

---

**Request more information or an in service:**

To request a presentation, or a product demo or to obtain more information about Fibryga, HCPs can visit the self-service portal [here. www.fibrygaresources.ca](http://www.fibrygaresources.ca)



**Important Safety Information:**

As with all fibrinogen preparations, Fibryga® is contraindicated in patients who have manifested severe immediate hypersensitivity reactions, including anaphylaxis to any product ingredient or component of the container.

For complete prescribing information, refer to the complete Fibryga® Product Monograph. For additional information on Fibryga® please visit our [www.fibrygaresources.ca](http://www.fibrygaresources.ca) or if you have any medical inquiries please contact medical information service by email [medinfo.canada@octapharma.com](mailto:medinfo.canada@octapharma.com) or call 1-888-438-0488.

Sri Adapa  
General Manager

**References:**

- 1) Fibryga® Product Monograph, November 19, 2020

---

Octapharma Canada Inc.  
214 King Street West  
Suite 308  
Toronto, ON M5H 3S6

Phone: (416) 531-5533  
Email: [info@octapharma.ca](mailto:info@octapharma.ca)

---